NCT05835921 Enhancing Prospective Thinking in Early Recovery
| NCT ID | NCT05835921 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Indiana University |
| Condition | Stimulant Use |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-03-28 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2023-03-28 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to use a novel virtual reality intervention to test for efficacy in reducing alcohol use and increasing abstinence, with concomitant increases in future self-identification, future time perspective, and delay-of-reward, in early recovering stimulant use disorder (SUD) persons. The main question\[s\] this trial aims to answer are: Will the Virtual Reality (VR) intervention decrease the number of stimulant use days? Will the VR intervention produce longer abstinence periods during follow-up visits? Will the VR intervention increase alcohol abstinence rates? Will the VR intervention increase future self-identification? Will the VR intervention increase self-reported future time perspective? Will the VR intervention increase preference for delayed rewards in a laboratory delay discounting task on the study day? Will the VR intervention produce gains in the behavioral effects of future self-identification, future time perspective, and delayed rewards at the 30-day and 6-month follow-ups? Researchers will compare the experimental and control groups to see if there are differences in the results for the questions outlined above.
Eligibility Criteria
Inclusion Criteria: * Abstinence between ≥14 days and ≤1 year * At least 18 years old * Verbal endorsement of commitment to recovery * Outpatient * Psychotropic drugs for SUD-comorbidity * Drug/alcohol abstinence ≥ 24 hours at the time of the study day visit * English comprehension Exclusion Criteria: * Unstable medical disorders * Less than 18 years old * Habitual drug use * Mu-opioid drugs * Smell/taste disorders * Unstable psychiatric conditions * Extravagant/elaborate face tattoos
Contact & Investigator
Brandon G Oberlin, PhD
PRINCIPAL INVESTIGATOR
Indiana University
Frequently Asked Questions
Who can join the NCT05835921 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stimulant Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05835921 currently recruiting?
Yes, NCT05835921 is actively recruiting participants. Contact the research team at sturo@iu.edu for enrollment information.
Where is the NCT05835921 trial being conducted?
This trial is being conducted at Indianapolis, United States.
Who is sponsoring the NCT05835921 clinical trial?
NCT05835921 is sponsored by Indiana University. The principal investigator is Brandon G Oberlin, PhD at Indiana University. The trial plans to enroll 200 participants.